The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- US FDA Approves Xtandi for Chemotherapy-Naïve Patients with Metastatic CRPC: Astellas
September 12, 2014
- Sawai to Comarket Sandoz’s Filgrastim Biosimilar
September 11, 2014
- Eisai Partners with Kyorin for Utilization of Eisai's Compound Library in Antibacterial Field
September 11, 2014
- Eli Lilly Japan, Hitachi Ink Sales Deal for Radiopharmaceutical Synthesizer for AD-Related Protein Imaging in Japan
September 10, 2014
- Shionogi to Realign Japan Sales Teams, Heed Regional Demands
September 10, 2014
- Zeria’s PMS Treatment Prefemin Now on Sale as “Drug Requiring Guidance”
September 10, 2014
- Janssen Discloses 2013 Payments of 8.3 Billion Yen to Healthcare Professionals
September 10, 2014
- Otsuka to Launch Deltyba on September 26; Launch Delayed in Anticipation of Revised TB Treatment Guidelines
September 10, 2014
- Medical & Biological Lab Seeking Partner for Dengue Fever Drug Development
September 9, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
September 9, 2014
- Ethical Drug Sales Down 3.0% in July: Crecon Report
September 9, 2014
- Ono, Bristol-Myers Sue Merck over Anti-PD-1 Antibody Patent
September 9, 2014
- Chugai Launches ALK Inhibitor Alecensa
September 9, 2014
- Pfizer Japan, Astellas to Terminate Copromotion Deal for Caduet in March Next Year
September 9, 2014
- MSD Sales Structure Now Tailored to Local Healthcare Needs: Pres.
September 8, 2014
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Meiji Seika Pharma, Takeda to Copromote Insomnia Treatment Rozerem from October
September 8, 2014
- Bayer Yakuhin Files Eylea for Macular Edema Secondary to Branch Retinal Vein Occlusion
September 8, 2014
- Takeda Files Leuplin 6-Month Depot Formulation in Japan
September 8, 2014
- MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing
September 5, 2014
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…